Zoetis (NYSE:ZTS) Reaches New 12-Month Low at $153.20

Zoetis Inc. (NYSE:ZTSGet Rating) reached a new 52-week low during trading on Tuesday . The company traded as low as $153.20 and last traded at $153.20, with a volume of 3722 shares trading hands. The stock had previously closed at $157.19.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Stifel Nicolaus reduced their price target on Zoetis from $275.00 to $225.00 and set a “buy” rating on the stock in a research report on Friday, June 24th. Piper Sandler assumed coverage on Zoetis in a research report on Monday, July 11th. They issued an “overweight” rating and a $205.00 price target on the stock. The Goldman Sachs Group reduced their price target on Zoetis from $208.00 to $202.00 and set a “buy” rating on the stock in a research report on Thursday, July 21st. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Finally, William Blair restated an “outperform” rating on shares of Zoetis in a research report on Friday, August 5th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $224.00.

Zoetis Trading Down 1.1 %

The business has a 50 day moving average of $168.03 and a two-hundred day moving average of $173.80. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.46 and a current ratio of 2.18. The firm has a market capitalization of $70.80 billion, a price-to-earnings ratio of 34.29, a P/E/G ratio of 2.74 and a beta of 0.77.

Zoetis (NYSE:ZTSGet Rating) last posted its quarterly earnings results on Thursday, August 4th. The company reported $1.20 earnings per share for the quarter, missing analysts’ consensus estimates of $1.22 by ($0.02). Zoetis had a return on equity of 49.03% and a net margin of 26.14%. The firm had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.03 billion. During the same period last year, the company posted $1.19 earnings per share. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. Equities analysts predict that Zoetis Inc. will post 5.01 EPS for the current year.

Insider Transactions at Zoetis

In other news, CEO Kristin C. Peck sold 311 shares of the stock in a transaction that occurred on Thursday, July 7th. The stock was sold at an average price of $180.00, for a total value of $55,980.00. Following the completion of the sale, the chief executive officer now directly owns 39,743 shares of the company’s stock, valued at $7,153,740. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CEO Kristin C. Peck sold 311 shares of the stock in a transaction that occurred on Thursday, July 7th. The stock was sold at an average price of $180.00, for a total value of $55,980.00. Following the completion of the sale, the chief executive officer now directly owns 39,743 shares of the company’s stock, valued at $7,153,740. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Roxanne Lagano sold 4,334 shares of the stock in a transaction that occurred on Monday, June 27th. The stock was sold at an average price of $175.00, for a total value of $758,450.00. Following the completion of the sale, the executive vice president now directly owns 23,687 shares of the company’s stock, valued at $4,145,225. The disclosure for this sale can be found here. Insiders sold a total of 16,501 shares of company stock valued at $2,949,073 over the last ninety days. 0.12% of the stock is currently owned by insiders.

Institutional Trading of Zoetis

Several institutional investors and hedge funds have recently modified their holdings of the stock. American National Bank increased its position in shares of Zoetis by 469.2% during the second quarter. American National Bank now owns 148 shares of the company’s stock valued at $25,000 after acquiring an additional 122 shares during the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its position in shares of Zoetis by 430.8% during the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after acquiring an additional 112 shares during the last quarter. Worth Asset Management LLC purchased a new stake in shares of Zoetis during the first quarter valued at approximately $26,000. Financial Management Professionals Inc. increased its position in shares of Zoetis by 117.4% during the first quarter. Financial Management Professionals Inc. now owns 150 shares of the company’s stock valued at $28,000 after acquiring an additional 81 shares during the last quarter. Finally, Hanson & Doremus Investment Management increased its position in shares of Zoetis by 713.6% during the first quarter. Hanson & Doremus Investment Management now owns 179 shares of the company’s stock valued at $34,000 after acquiring an additional 157 shares during the last quarter. 91.05% of the stock is owned by hedge funds and other institutional investors.

Zoetis Company Profile

(Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

See Also

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.